GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus.
about
Dipeptidyl-peptidase (DPP)-4 inhibitors or glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitusGlucagon and heart in type 2 diabetes: new perspectivesImplications of Hydrogen Sulfide in Glucose Regulation: How H2S Can Alter Glucose Homeostasis through Metabolic HormonesThe treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapiesGlucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes: Past, present, and futureLong-term safety and efficacy of insulin degludec in the management of type 2 diabetesAdverse Effects of GLP-1 Receptor AgonistsPancreatic α-Cell Dysfunction in Type 2 Diabetes: Old Kids on the BlockAvoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetesThe class B G-protein-coupled GLP-1 receptor: an important target for the treatment of type-2 diabetes mellitusDulaglutide: an evidence-based review of its potential in the treatment of type 2 diabetesBasal insulin combined incretin mimetic therapy with glucagon-like protein 1 receptor agonists as an upcoming option in the treatment of type 2 diabetes: a practical guide to decision makingIncretins and the intensivist: what are they and what does an intensivist need to know about them?The evolution of insulin glargine and its continuing contribution to diabetes careLixisenatide as add-on therapy to basal insulinProtection against the Metabolic Syndrome by Guar Gum-Derived Short-Chain Fatty Acids Depends on Peroxisome Proliferator-Activated Receptor γ and Glucagon-Like Peptide-1Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic SuccessesGlucagon-like peptide-1 receptor agonists favorably address all components of metabolic syndromeEfficacy and safety of dulaglutide in patients with type 2 diabetes: a meta-analysis and systematic reviewTreatment intensification in patients with inadequate glycemic control on basal insulin: rationale and clinical evidence for the use of short-acting and other glucagon-like peptide-1 receptor agonistsStructural Determinants of Binding the Seven-transmembrane Domain of the Glucagon-like Peptide-1 Receptor (GLP-1R)Simple bioconjugate chemistry serves great clinical advances: albumin as a versatile platform for diagnosis and precision therapyPharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.Investigational anti-hyperglycemic agents: the future of type 2 diabetes therapy?The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.Once-weekly albiglutide in the management of type 2 diabetes: patient considerations.GLP-1 released to the mesenteric lymph duct in mice: effects of glucose and fat.A system model of the effects of exercise on plasma Interleukin-6 dynamics in healthy individuals: Role of skeletal muscle and adipose tissue.Expression of CTRP3, a novel adipokine, in rats at different pathogenic stages of type 2 diabetes mellitus and the impacts of GLP-1 receptor agonist on itIndirect comparison of lixisenatide versus neutral protamine Hagedorn insulin as add-on to metformin and sulphonylurea in patients with type 2 diabetes mellitus.Glycemic variability and oxidative stress: a link between diabetes and cardiovascular disease?Lixisenatide resensitizes the insulin-secretory response to intravenous glucose challenge in people with type 2 diabetes--a study in both people with type 2 diabetes and healthy subjects.Comparison of insulin lispro protamine suspension versus insulin glargine once daily added to oral antihyperglycaemic medications and exenatide in type 2 diabetes: a prospective randomized open-label trial.Incretin-based therapies in prediabetes: Current evidence and future perspectivesThe clinical development program of lixisenatide: a once-daily glucagon-like Peptide-1 receptor agonist.Chronic continuous exenatide infusion does not cause pancreatic inflammation and ductal hyperplasia in non-human primates.Mechanisms underlying weight loss and metabolic improvements in rodent models of bariatric surgery.Efficacy and safety of lixisenatide in Japanese patients with type 2 diabetes mellitus inadequately controlled by sulfonylurea with or without metformin: Subanalysis of GetGoal-SSemaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel.Gut-Brain Endocrine Axes in Weight Regulation and Obesity Pharmacotherapy
P2860
Q24185805-09BFE6DA-4861-4445-A673-7F2D964581A5Q26738580-9913378F-AA4A-4AE2-A267-5841EF524806Q26740339-E755CDAC-7BBD-448A-B77A-29FA220B19DAQ26744317-31F65370-35AD-4BBE-B8DE-1B1B7A125976Q26752699-A0B1A2A1-6D40-4029-AB7C-A9591CCE4927Q26784381-18EE521B-2FB8-4FD3-B6CE-CF24F88B33E4Q26801346-C42D6595-8903-45C4-88CC-83858EEFE74BQ26825393-BE6537EA-851C-4DA6-9786-A1EFBBACE3BAQ26827955-32FACE2F-9735-47F1-9F9E-894BCB9AFD31Q26828940-F99E4D90-A217-4D7B-8D0F-9A04B802A201Q26861768-7379A279-4604-4708-AE92-B3AEE5BEF0EEQ26992979-BB62F654-FA8A-4D56-A04A-59AAC1E2C0BEQ26995464-0C86FDBC-7645-42A8-8911-B69E510C8565Q26999454-DFC371CA-A503-48AA-9800-A9E93D9F064EQ27007547-F466B318-D2CF-4484-B0DF-75CA3C6E8368Q27321785-245386A2-50C0-448B-92B2-9BB8E3CBEE57Q28067465-B41556A7-AC5F-4FA0-BE36-B11F46149326Q28070416-6FC33C37-53F9-4E39-81D4-1683B5B90591Q28076726-2B946F9D-566E-46A7-B949-330253C9E864Q28077026-9CDA6CEE-0922-4F43-B1B8-48FDD9BD6C59Q28274664-C41ED867-7E56-40D5-8C17-619F374EC841Q28397980-8DE2E497-AF8B-458B-A258-E541B446994BQ30249371-B14395A9-1CE3-47A3-AC11-20EE3F479641Q30426407-92C6761D-0352-4BFC-8FD4-E04D2C3A4BA1Q30596646-4ACA54F9-D398-4F5B-BFC9-D5B99DFF9E83Q33728226-95041586-E0F4-48A7-8BEF-834D0CBA18F9Q33745485-5F8E5D88-35CB-4C97-951A-4662B9D8EEDBQ33898505-75FAD3F7-BD4B-4568-88C3-0FE05F8D97F8Q34081175-A56C8195-5327-4A63-ABD2-8F1FDB9DFE47Q34368524-1554108C-AF65-4AA1-A761-6D51A95636FCQ34486820-E3D19446-220B-45C6-B3BA-811ED8D828C5Q34543003-343563F4-0AE7-4D10-8715-CB5659403BC4Q34543057-F6869E4F-27C1-4592-88B6-41C1B57DE6AAQ34699191-5D179638-8E7D-482A-A3C1-449E8311FA50Q34726309-98D8B2A4-D397-4212-802D-924A55053D9DQ34780873-738E7C54-0BD4-470A-91E9-80CE66AD4F28Q34898952-BC055E9A-B877-4557-A33E-0F5EED60DC75Q35192193-17B5659A-72D2-458F-B5BE-F99882F04618Q35565133-F717C969-06B4-4C5D-AB7F-B23CC707B86DQ35667150-C7C1B992-4786-4A24-9E2C-8A15BEF66C53
P2860
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus.
@en
type
label
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus.
@en
prefLabel
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus.
@en
P356
P1476
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus.
@en
P2093
Juris J Meier
P2888
P304
P356
10.1038/NRENDO.2012.140
P577
2012-09-04T00:00:00Z